BioSpace News Archive

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that management will present at two upcoming virtual conferences in March.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, provided a corporate update and reported fourth quarter and full year financial results for the periods ended December 31, 2020.

Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR), in 2021 On track to submit an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML) Intends to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for the treatment of hereditary angioedema (HAE)

– Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM)

Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively. Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter. Pursuing CAPLYTA label expansion including bipolar depression and major depressive disorder:

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management team will present and host meetings with investors at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021

M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its support for Rare Disease Day 2021 and commitment to the rare disease community.

10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference.

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences:

Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.